AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Attention and Eye Movement in Parkinson's Disease

RecruitingNAAges 19 Years - 90 YearsAllUniversity of Nebraska
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this observational and interventional study is to understand how therapeutic deep brain stimulation (DBS) affects attention, perception and cognition in participants with Parkinson's disease (PD) and non-PD movement disorders, including essential tremor (ET) and dystonia (DT). The main questions it aims to answer are: * Does impaired control of attention and eye movement in PD alter how social cues are perceived and interpreted? * Does therapeutic DBS improve or worsen attentional and perceptual deficits for social cues in PD, ET and DT? * Can DBS be optimized to restore normal attentional control in PD while remaining an effective therapy for other aspects of the disorder. * What do parts of the brain targeted by DBS contribute to the control of attention? Using an eye tracking camera, investigators will study how participants with PD, ET and DT look at and perceive facial

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria * All Participants (Aim 1): * Ability and willingness to provide signed informed consent for this study * Ability to express perceptual judgments through a button press or mouse- controlled computerized slider * Age 19 - 90 years * DBS Participants (Aim 1): * Diagnosis of idiopathic Parkinson's disease (PD), essential tremor (ET) or dystonia (DT). * Scheduled for new implantation of a therapeutic DBS device targeted to subthalamic nucleus (STN), ventral intermediate nucleus of thalamus (VIM) or internal globus pallidus (GPi) * Comparison Participants (Aim 1): o Selection by age matching to participants in PD group * Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 2): * Ability and willingness to provide signed informed consent for this study * Ability to express perceptual judgments through a button press or mouse- controlled computerized slider * Age 19 - 90 years * Scheduled for awake DBS implantation with clinical micro-electrode recordings (MER) * Willing and able to engage in tasks during an awake surgical procedure * Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 3): * Ability and willingness to provide signed informed consent for this study * Ability to express perceptual judgments through a button press or mouse- controlled computerized slider * Age 19 - 90 years * Willing to undergo acute manipulations of DBS * Able to tolerate acute changes of DBS Exclusion Criteria * All Participants (Aim 1): * Corrected visual acuity insufficient to perceptually judge face stimuli * Inability to understand task instructions or complete task requirements * DBS Participants (Aim 1): o Insufficient therapeutic control of motor symptoms to engage in tasks requiring button press or use of a mouse to control a slider * Healthy Comparison Participants (Aim 1): o History of neurodegenerative disorder * Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 2): * Corrected visual acuity insufficient to perceptually judge face stimuli * Inability to understand task instructions or complete task requirements * Not undergoing awake DBS implantation * Uncorrected visual acuity insufficient to perceptually judge face stimuli * Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 3): * Corrected visual acuity insufficient to perceptually judge face stimuli * Inability to understand task instructions or complete task requirements * Failure of DBS to achieve a therapeutic effect on motor symptoms
๐Ÿ’Š

What it tests

  • Normal therapeutic DBS
  • Reduced current DBS
  • Reduced frequency DBS
๐Ÿ“

Where

1 site
University of Nebraska Medical Center
Omaha, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy